There is an urgent need to identify non-demented individuals at the highest risk of progressing to Alzheimer’s dementia. In this talk, I will introduce the polygenic hazard score (PHS) derived using a survival analysis framework for predicting Alzheimer’s dementia age of onset. I will then present findings showing that PHS is associated with neuroimaging biomarkers, cognitive decline, and clinical progression. The potential utility of PHS in the clinic and for clinical trials will also be discussed.